Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line
Author:
Funder
Bilecik Şeyh Edebali Üniversitesi
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11033-022-08034-4.pdf
Reference49 articles.
1. Yang Y, Zhou H, Liu W et al (2018) Ganoderic acid a exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. Oncol Lett 16:6515–6521. https://doi.org/10.3892/ol.2018.9475
2. Franklin DA, James JL, Axelrod ML, Balko JM (2020) MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression. Cancer Drug Resist 3:603–612. https://doi.org/10.20517/cdr.2019.109
3. Khan Mohammad A, Jain Vineet K, JA Md. Rizwanullah, KJ (2019) PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today 24:2181–2191. https://doi.org/10.1016/j.drudis.2019.09.001
4. He J, McLaughlin RP, van der Noord V et al (2019) Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer. Breast Cancer Res Treat 178:263–274. https://doi.org/10.1007/s10549-019-05380-z
5. Jhan JR, Andrechek ER (2017) Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 18:1595–1609. https://doi.org/10.2217/pgs-2017-0117
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1;Molecular Biology Reports;2024-07-22
2. Combination of microparticles vaccine with MSI-1436 exerts a strong immune response for hepatocellular carcinoma;Journal of Leukocyte Biology;2024-07-16
3. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action;International Journal of Molecular Sciences;2024-06-06
4. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit the JAK2/STAT5 signaling via downregulating Bcl-2 and Mcl-1 on BT474 breast cancer cells;2024-04-24
5. Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission;Cell Death & Disease;2024-02-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3